Shionogi:Production of corona oral medicine: Approval application by the end of the year
October 8, 2021
Shionogi Pharmaceutical
Isao Teshiroki President
Select a global expansion partner in consultation with 6-7 overseas pharmaceutical companies
With a view to collaborating with “Merck, the US that leads the development of therapeutic drugs”
Shionogi aims to apply for approval by the end of the year for an oral therapeutic drug (drinking drug) for the new coronavirus.
On October 6, he announced that he would start commercial production of the drug by the end of this month.
Coronavirus new drug:
For global expansion
With overseas pharmaceutical companies
It has revealed that it has begun negotiations on a partnership.
Bloomberg Interview:
The small molecule therapeutic drug developed by Shionogi is
There are many production processes to develop,
It is necessary to make it early without waiting for approval.
Moreover,
After global expansion, the company said it can expect annual sales of up to $ 2 billion (¥ 223 billion).
Final clinical trial:
On September 27, Shionogi began a second- and third-stage clinical trial of a therapeutic drug in Japan.
Evaluate results in December:
The results will be evaluated in December after observing the time to recovery of symptoms in mildly ill patients and the incidence rate of asymptomatic patients.
Development of corona remedies:
In addition to Shionogi in Japan
US Merck and Pfizer,
Swiss Roche (Chugai exclusively developed and sold in Japan)
Participating in the competition for the development of corona drugs.
Bloomberg
https://www.bloomberg.co.jp/news/articles/2021-10-07/R0HBQJT0G1KW01